Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block

Journal of Physiology

Volumn 581, Issue 1, 2007, Pages 107-128

  Dravid, Shashank M ^a   Erreger, Kevin ^b   Yuan, Hongjie ^a   Nicholson, Katherine ^c   Le, Phuong ^a   Lyuboslavsky, Polina ^a   Almonte, Antoine ^a   Murray, Ernest ^c   Mosely, Cara ^c   Barber, Jeremy ^a   French, Adam ^a   Balster, Robert ^d   Murray, Thomas F ^e   Traynelis, Stephen F ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHENYLCYCLOHEXYLAMINE; AMANTADINE; AMINOACRIDINE; ANTICONVULSIVE AGENT; APTIGANEL; DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; ETICYCLIDINE; FLUROTHYL; ION CHANNEL; KETAMINE; LACTATE DEHYDROGENASE; LEVOMETHORPHAN; LEVORPHANOL; MEMANTINE; N METHYL 1 PHENYLCYCLOHEXYLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N PROPYL 1 PHENYLCYCLOHEXYLAMINE; PENTAMIDINE; REMACIMIDE; UNCLASSIFIED DRUG; CYCLIC AMP DEPENDENT PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; CHANNEL GATING; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG BINDING SITE; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; EMBRYO; EPILEPSY; FEMALE; HUMAN; HUMAN CELL; LOCOMOTION; MOLECULAR INTERACTION; MOLECULAR SENSOR; MOUSE; NEUROPROTECTION; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; PROTON TRANSPORT; PSYCHOSIS; RAT; RECEPTOR BLOCKING; STRUCTURE ANALYSIS; ADULT; BINDING SITE; CLONIC SEIZURE; DRUG POTENCY; ENZYME MECHANISM; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; PH; PROTEIN DETERMINATION; PROTEIN FUNCTION; TONIC CLONIC SEIZURE;

ANIMALS; CELL LINE; DIZOCILPINE MALEATE; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; ION CHANNEL GATING; ION CHANNELS; MALE; MICE; MICE, INBRED C57BL; PATCH-CLAMP TECHNIQUES; PROTONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; STEREOISOMERISM; XENOPUS LAEVIS;

EID: 34248228746     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.124958     Document Type: Article

References (105)

1. Albers GW, Goldberg MP & Choi DW (1989). N-Methyl-D-aspartate antagonists: Ready for clinical trial in brain ischemia? Ann Neurol 25, 398-403.
2. Andine P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E & Sandberg M (1999). Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 290, 1393-1408.
3. Antonov SM, Gmiro VE & Johnson JW (1998). Binding sites for permeant ions in the channel of NMDA receptors and their effects on channel block. Nat Neurosci 1, 451-461.
4. 2+. Proc Natl Acad Sci U S A 96, 14571-14576.
5. Balster RL (1991). Drug abuse potential evaluation in animals. Br J Addict 86, 1549-1558.
6. Balster RL & Willetts J (1988). Receptor mediation of the discriminative stimulus properties of phencyclidine and σ-opioid agonists. Psychopharmacol Ser 4, 122-135.
7. Banke TG, Dravid SM & Traynelis SF (2005). Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J Neurosci 25, 42-51.
8. Baselt RC (2004). Disposition of Toxic Drugs and Chemicals in Man, 7th edn. Biomedical Publications, Foster City, CA, USA.
9. Benveniste M & Mayer ML (1992). Effect of extracellular pH on the potency of N-methyl-D-aspartic acid receptor competitive antagonists. Mol Pharmacol 42, 679-686.
10. Blanpied TA, Boeckman FA, Aizenman E & Johnson JW (1997). Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 77, 309-323.
11. Blanpied TA, Clarke RJ & Johnson JW (2005). Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25, 3312-3322.
12. Bolshakov KV, Gmiro VE, Tikhonov DB & Magazanik LG (2003). Determinants of trapping block of N-methyl-D-aspartate receptor channels. J Neurochem 87, 56-65.
13. Bormann J (1989). Memantine is a potent blocker of N-methyl-D -aspartate (NMDA) receptor channels. Eur J Pharmacol 166, 591-592.
14. Casadio R & Melandri BA (1977). The behavior of 9-aminoacridine as an indicator of transmembrane pH difference in liposomes of natural bacterial phospholipids. J Bioenerg Biomembr 9, 17-29.
15. Chesler M & Kaila K (1992). Modulation of pH by neuronal activity. Trends Neurosci 15, 396-402.
16. Choi DW (1985). Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett 58, 293-297.
17. Choi DW (1992). Excitotoxic cell death. J Neurobiol 23, 1261-1276.
18. 2+ inhibition of the NMDA receptor. Neuron 23, 171-180.
19. Church J, Zeman S & Lodge D (1988). The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats. Anesthesiology 69, 702-709.
20. Clarke RJ & Johnson JW (2006). NMDA receptor NR2 subunit dependence of the slow component of magnesium unblock. J Neurosci 26, 5825-5834.
21. Costa AC & Albuquerque EX (1994). Dynamics of the actions of tetrahydro-9-aminoacridine and 9-aminoacridine on glutamatergic currents: Concentration-jump studies in cultured rat hippocampal neurons. J Pharmacol Exp Ther 268, 503-514.
22. Dilmore JG & Johnson JW (1998). Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine. Biophys J 75, 1801-1816.
23. Dingledine R, Borges K, Bowie D & Traynelis SF (1999). The glutamate receptor ion channels. Pharmacol Rev 51, 7-61.
24. Dirnagl U, Iadecola C & Moskowitz MA (1999). Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 22, 391-397.
25. Dravid SM, Baden DG & Murray TF (2004). Brevetoxin activation of voltage-gated sodium channels regulates Ca dynamics and ERK1/2 phosphorylation in murine neocortical neurons. J Neurochem 89, 739-749.
26. Ellison G (1995). The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioural and anatomical models of the dementias. Brain Res Brain Res Rev 20, 250-267.
27. Erdo SL & Schafer M (1991). Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 198, 215-217.
28. Erreger K, Chen PE, Wyllie DJ & Traynelis SF (2004). Glutamate receptor gating. Crit Rev Neurobiol 16, 187-224.
29. Erreger K, Dravid SM, Banke TG, Wyllie DJ & Traynelis SF (2005 a). Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J Physiol 563, 345-358.
30. Erreger K, Geballe MT, Dravid SM, Snyder JP, Wyllie DJ & Traynelis SF (2005 b). Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci 25, 7858-7866.
31. France CP, Moerschbaecher JM & Woods JH (1991). MK-801 and related compounds in monkeys: Discriminative stimulus effects and effects on a conditional discrimination. J Pharmacol Exp Ther 257, 727-734.
32. Freudenthaler S, Meineke I, Schreeb KH, Boakye E, Gundert-Remy U & Gleiter CH (1998). Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol 46, 541-546.
33. Genovese RF & Lu XC (1991). Effects of MK-801 stereoisomers on schedule-controlled behavior in rats. Psychopharmacology (Berl) 105, 477-480.
34. Geter-Douglass B & Witkin JM (1997). Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology (Berl) 133, 43-50.
35. Giffard RG, Monyer H, Christine CW & Choi DW (1990). Acidosis reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose deprivation neuronal injury in cortical cultures. Brain Res 506, 339-342.
36. Gill R, Foster AC & Woodruff GN (1987). Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci 7, 3343-3349.
37. Halliwell RF, Peters JA & Lambert JJ (1989). The mechanism of action and pharmacological specificity of the anticonvulsant NMDA antagonist MK-801: A voltage clamp study on neuronal cells in culture. Br J Pharmacol 96, 480-494.
38. Higgins GA, Ballard TM, Huwyler J, Kemp JA & Gill R (2003). Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: Evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology 44, 324-341.
39. Hille B (1977). The pH-dependent rate of action of local anesthetics on the node of Ranvier. J Gen Physiol 69, 475-496.
40. Hiramatsu M, Cho AK & Nabeshima T (1989). Comparison of the behavioural and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166, 359-366.
41. Holtzman SG (1990). Caffeine as a model drug of abuse. Trends Pharmacol Sci 11, 355-356.
42. Huettner JE & Bean BP (1988). Block of N-methyl-D -aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels. Proc Natl Acad Sci U S A 85, 1307-1311.
43. Jahr CE (1992). High probability opening of NMDA receptor channels by L -glutamate. Science 255, 470-472.
44. Janssens N & Lesage AS (2001). Glutamate receptor subunit expression in primary neuronal and secondary glial cultures. J Neurochem 77, 1457-1474.
45. Johnson JW & Kotermanski SE (2006). Mechanism of action of memantine. Curr Opin Pharmacol 6, 61-67.
46. Kashiwagi K, Pahk AJ, Masuko T, Igarashi K & Williams K (1997). Block and modulation of N-methyl-D-aspartate receptors by polyamines and protons: Role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits. Mol Pharmacol 52, 701-713.
47. Khanna JM, Wu PH, Weiner J & Kalant H (1991). NMDA antagonist inhibits rapid tolerance to ethanol. Brain Res Bull 26, 643-645.
48. Kochhar A, Zivin JA & Mazzarella V (1991). Pharmacologic studies of the neuroprotective actions of a glutamate antagonist in ischemia. J Neurotrauma 8, 175-186.
49. Koek W, Woods JH & Colpaert FC (1990). N-Methyl-D-aspartate antagonism and phencyclidine-like activity: A drug discrimination analysis. J Pharmacol Exp Ther 253, 1017-1025.
50. Koh JY & Choi DW (1987). Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Meth 20, 83-90.
51. Kornhuber J, Weller M, Schoppmeyer K & Riederer P (1994). Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43, 91-104.
52. Lee JM, Zipfel GJ & Choi DW (1999). The changing landscape of ischaemic brain injury mechanisms. Nature 399, A7-A14.
53. 3 H]MK-801 in heterologously expressed NMDA receptors. Neuropharmacology 49, 1-16.
54. Li JH, Wang YH, Wolfe BB, Krueger KE, Corsi L, Stocca G & Vicini S (1998). Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons. Eur J Neurosci 10, 1704-1715.
55. Low CM, Lyuboslavsky P, French A, Le P, Wyatte K, Thiel WH, Marchan EM, Igarashi K, Kashiwagi K, Gernert K, Williams K, Traynelis SF & Zheng F (2003). Molecular determinants of proton-sensitive N-methyl-D -aspartate receptor gating. Mol Pharmacol 63, 1212-1222.
56. Low CM, Zheng F, Lyuboslavsky P & Traynelis SF (2000). Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D -aspartate NR1/NR2A receptors. Proc Natl Acad Sci U S A 97, 11062-11067.
57. MacDonald JF, Bartlett MC, Mody I, Pahapill P, Reynolds JN, Salter MW, Schneiderman JH & Pennefather PS (1991). Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol 432, 483-508.
58. MacDonald JF & Nowak LM (1990). Mechanisms of blockade of excitatory amino acid receptor channels. Trends Pharmacol Sci 11, 167-172.
59. Meldrum BS, Akbar MT & Chapman AG (1999). Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res 36, 189-204.
60. Moffat AC, Osselton MD & Widdop B (2004). Clarke's Analysis of Drugs and Poisons, 3rd edn, vol. 2. Pharmaceutical Press, London.
61. Monaghan DT, Andaloro VJ & Skifter DA (1998). Molecular determinants of NMDA receptor pharmacological diversity. Prog Brain Res 116, 171-190.
62. Monaghan DT & Larsen H (1997). NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther 280, 614-620.
63. 2+-block site of the NMDA receptor channel. Nature 358, 673-675.
64. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF & Dingledine R (1998). Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1, 659-667.
65. Mott DD, Erreger K, Banke TG & Traynelis SF (2001). Open probability of homomeric murine 5-HT 3A serotonin receptors depends on subunit occupancy. J Physiol 535, 427-443.
66. Mozayani A (2003). Phencyclidine -effects on human performance and behavior. Forensic Sci Rev 15, 61-74.
67. Myers SJ, Geballe MT, Le P, Lyuboslavsky PN, Dingledine R, Snyder JP & Traynelis SF (2006). pH dependence of phosphono-derivative NMDA receptor antagonists. Abstract Viewer and Itinerary Planner, prog. no. 623.2. Society for Neuroscience 2006 Online.
68. Nedergaard M, Kraig RP, Tanabe J & Pulsinelli WA (1991). Dynamics of interstitial and intracellular pH in evolving brain infarct. Am J Physiol Regul Integr Comp Physiol 260, R581-R588.
69. Nicholson KL, Hayes BA & Balster RL (1999). Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 146, 49-59.
70. Obrenovitch TP & Urenjak J (1997). Is high extracellular glutamate the key to excitotoxicity in traumatic brain injury? J Neurotrauma 14, 677-698.
71. Pahk AJ & Williams K (1997). Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci Lett 225, 29-32.
72. Park CK, Nehls DG, Graham DI, Teasdale GM & McCulloch J (1988). The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 24, 543-551.
73. Parsons CG, Gruner R, Rozental J, Millar J & Lodge D (1993). Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32, 1337-1350.
74. Raffa RB, Ortegon ME, Robisch DM & Martin GE (1989). In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci 44, 1593-1599.
75. Sackin H, Nanazashvili M, Palmer LG, Krambis M & Walters DE (2005). Structural locus of the pH gate in the Kir1.1 inward rectifier channel. Biophys J 88, 2597-2606.
76. Sattler R, Charlton MP, Hafner M & Tymianski M (1998). Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71, 2349-2364.
77. Sattler R & Tymianski M (2001). Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol 24, 107-129.
78. ir 1.1) channels: Control by an Arg-Lys-Arg triad disrupted in antenatal Bartter syndrome. Proc Natl Acad Sci U S A 96, 15298-15303.
79. Schwarz W, Palade PT & Hille B (1977). Local anesthetics. Effect of pH on use-dependent block of sodium channels in frog muscle. Biophys J 20, 343-368.
80. Slater B, McCormack A, Avdeef A & Comer JE (1994). pH-metric log P. 4. Comparison of partition coefficients determined by HPLC and potentiometric methods to literature values. J Pharm Sci 83, 1280-1283.
81. Sobolevskii AI & Khodorov BI (2002). Blocker studies of the functional architecture of the NMDA receptor channel. Neurosci Behav Physiol 32, 157-171.
82. Sobolevsky AI, Koshelev SG & Khodorov BI (1999). Probing of NMDA channels with fast blockers. J Neurosci 19, 10611-10626.
83. Spector R (1988). Transport of amantadine and rimantadine through the blood-brain barrier. J Pharmacol Exp Ther 244, 516-519.
84. Stern P, Behe P, Schoepfer R & Colquhoun D (1992). Single-channel conductances of NMDA receptors expressed from cloned cDNAs: Comparison with native receptors. Proc Biol Sci 250, 271-277.
85. +. Proc Natl Acad Sci U S A 87, 6445-6449.
86. Thornberg SA & Saklad SR (1996). A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 16, 82-93.
87. Tombaugh GC & Sapolsky RM (1993). Evolving concepts about the role of acidosis in ischemic neuropathology. J Neurochem 61, 793-803.
88. Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P & Powers JL (1998). Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci 18, 6163-6175.
89. Traynelis SF & Cull-Candy SG (1990). Proton inhibition of N-methyl- D-aspartate receptors in cerebellar neurons. Nature 345, 347-350.
90. + sensitivity of excitatory amino acid receptor channels in rat cerebellar granule neurones. J Physiol 433, 727-763.
91. Traynelis SF & Wahl P (1997). Control of rat GluR6 glutamate receptor open probability by protein kinase A and calcineurin. J Physiol 503, 513-531.
92. Tricklebank MD, Singh L, Oles RJ, Preston C & Iversen SD (1989). The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167, 127-135.
93. Vyklicky L Jr, Vlachova V & Krusek J (1990). The effect of external pH changes on responses to excitatory amino acids in mouse hippocampal neurones. J Physiol 430, 497-517.
94. Wang CX & Shuaib A (2005). NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord 4, 143-151.
95. Wiley JL, Li H & Balster RL (1997). Discriminative stimulus effects of site-selective N-methyl-D-aspartate antagonists in NPC 17742-trained rats and squirrel monkeys. Psychopharmacology (Berl) 132, 382-388.
96. Willetts J & Balster RL (1988). Phencyclidine-like discriminative stimulus properties of MK-801 in rats. Eur J Pharmacol 146, 167-169.
97. 2+ interacts with structural determinants of the narrow constriction contributed by the NR1-subunit in the NMDA receptor channel. J Physiol 506, 33-52.
98. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN & Iversen LL (1986). The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A 83, 7104-7108.
99. Xu H, Yang Z, Cui N, Chanchevalap S, Valesky WW & Jiang C (2000). A single residue contributes to the difference between Kir4.1 and Kir1.1 channels in pH sensitivity, rectification and single channel conductance. J Physiol 528, 267-277.
100. Yamakura T, Sakimura K & Shimoji K (2000). N-Methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg 90, 928-932.
101. 2 and pH. J Gen Physiol 116, 33-45.
102. Yuan H, Erreger K, Dravid SM & Traynelis SF (2005). Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J Biol Chem 280, 29708-29716.
103. Zarei MM & Dani JA (1995). Structural basis for explaining open-channel blockade of the NMDA receptor. J Neurosci 15, 1446-1454.
104. Zheng F, Erreger K, Low CM, Banke T, Lee CJ, Conn PJ & Traynelis SF (2001). Allosteric interaction between the amino terminal domain and the ligand binding domain of NR2A. Nat Neurosci 4, 894-901.
105. 2+ block of the N-methyl-D-aspartate receptor channel. J Gen Physiol 117, 275-286.